Millions of People Will Soon Be Blindsided. Will You Be One of Them?

On April 20 at 7 p.m. ET, Louis Navellier and Matt McCall will reveal an event that’s about to rock the stock market and how you could use it to beat the markets by nearly 11X.

Tue, April 20 at 7:00PM ET

CRIS Stock News: Why Biotech Stock Curis Is Going Gangbusters

Curis (NASDAQ:CRIS) stock is taking off on Tuesday following news of positive data from a Phase 1 clinical trial.

Packs of blue and pink pills are piled on top of each other.

Source: Shutterstock

A news release from CRIS pinpoints the positive stock movement to preliminary results from its dose-escalation study of CA-4948. CA-4948 is a novel, small molecule IRAK4 kinase inhibitor used to treat patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).

According to the news release, CA-4948 has been successful in reducing marrow blast reductions in six patients. Of these six a total of two patients saw a marrow complete response. This had their blast count dropping from 23% to 1% and 11% to 2% following treatment.

It’s also worth noting that six of the seven patients taking part in the Curis study are keeping with it. That’s a positive sign as the Phase 1 study is seeking to determine appropriate dose levels of CA-4948 for a planned Phase 2 study.

James Dentzer, president and CEO of Curis, said this about the news boosting CRIS stock higher today.

“We are highly encouraged by the breadth of clinical activity with CA-4948 seen with this early data, especially as this study is both monotherapy and in a late line, relapsed/refractory population. Historically, monotherapy studies in AML and MDS have proven underwhelming; monotherapy studies in a relapsed/refractory setting have been especially challenging.”

Curis plans to announce additional data from the Phase 1 study in the second half of 2021.

CRIS stock was up 399.7% as of Tuesday morning.

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.

Article printed from InvestorPlace Media,

©2021 InvestorPlace Media, LLC